Skip to main content
SpringerLink
Log in

Perioperative Intravesical Therapy

  • Chapter
  • First Online:
Bladder Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 1048 Accesses

Abstract

For well over a decade, the results of prospective, randomized, controlled clinical trials performed primarily outside the United States have shown that intravesical instillation of chemotherapeutic agents immediately after transurethral resection of bladder tumor (TURB) decreases the likelihood of tumor recurrence, particularly for patients with newly diagnosed bladder cancers. Despite this, guidelines by the American Urological Association do not advocate its use as standard of care for the treatment of superficial bladder cancer while the European Association of urology does. We have reviewed the world literature and feel that there is ample evidence to recommend the routine use of intravesical mitomycin C after transurethral resection of bladder tumors in the United States.

Using a health-care based medical research database there is significant under-utilization of perioperative intravesical chemotherapy by American urologists. Reasons for this policy not being incorporated into standard practice, including barriers to its acceptance and performance, are unclear. Furthermore, an analysis for potential cost savings with its incorporation in routine care of patients with low-grade superficial bladder cancer revealed a $24.8 million cost savings to the American health care system per year. We therefore conclude that there is ample evidence to show that immediate intravesical chemotherapy can decrease the likelihood of tumor recurrence and adopting this policy would significantly lower the cost of care for bladder cancer in the U.S.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. 1.Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2):106–130.

    Article  PubMed  Google Scholar 

  2. 2.Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 2004; 22(2):86–92.

    PubMed  Google Scholar 

  3. 3.Messing EM. Urothelial tumors of the urinary tract. In: Walsh PC et al editor. Campbell's Urology. Philadelphia: WB Saunders; 2002, pp. 2732–2784.

    Google Scholar 

  4. Malkowicz S. Management of Superficial Bladder Cancer. In: Walsh PC et al editor. Campbell's Urology. Phildaelphia: WB Saunders; 2002, pp. 2785–2802.

    Google Scholar 

  5. 5.Marshall VF. Symposium on bladder tumors: Current clinical problems regarding bladder tumors. Cancer 1956; 9:543–550.

    Article  CAS  PubMed  Google Scholar 

  6. 6 Borhan A, Reeder JE, O'Connell MJ et al. Grade progression and regression in recurrent urothelial cancer. J Urol 2003; 169(6):2106–2109.

    Article  CAS  PubMed  Google Scholar 

  7. 7.Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149(4):749–752.

    CAS  PubMed  Google Scholar 

  8. 8.Shuin T, Kubota Y, Noguchi S et al A phase II study of prophylactic intravesical chemotherapy with 4ć-epirubicin in recurrent superficial bladder cancer: comparison of 4ć-epirubicin and adriamycin. Cancer Chemother Pharmacol 1994; 35 Suppl:S52–S56.

    Article  PubMed  Google Scholar 

  9. Klan R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991; 146(2):316–318.

    CAS  PubMed  Google Scholar 

  10. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999; 161(4):1120–1123.

    Article  CAS  PubMed  Google Scholar 

  11. Beer E. Removal of neoplasms of the urinary bladder: a new method employing high frequency (Oudin) currents through a catheterizing cystoscope. JAMA 1910; 54:1768–1769.

    Google Scholar 

  12. Beer E. Tumors of the Urinary Bladder. Baltimore: William Wood; 1935.

    Google Scholar 

  13. Bransford Lewis. AUA Histroy of Urology. McAllen, Texas: Wilkins and Wilkins; 1933.

    Google Scholar 

  14. Chinegwundoh F. The Early Surgical Histroy of Bladder Cancer. In: Mattelaer J, editor. de Historia Urologiae Europaeae, 4 ed. Belgium: European Association of Urology; 1997, pp. 163–174.

    Google Scholar 

  15. Hinman F. The Principles and Practice of Urology, 1st ed. Philadelphia: W.B. Saunders; 1937.

    Google Scholar 

  16. Young HH, Davis D. Young's Practice of Urology, 1st ed. Philadelphia: W.B. Saunders; 1926.

    Google Scholar 

  17. Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 1992; 19(3):429–433.

    CAS  PubMed  Google Scholar 

  18. Herr HW. Intravesical therapy. A critical review. Urol Clin North Am 1987; 14(2):399–404.

    CAS  PubMed  Google Scholar 

  19. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF, Jr. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141(1):22–29.

    CAS  PubMed  Google Scholar 

  20. Herr HW, Wartinger DD, Fair WR, Oettgen HF. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol 1992; 147(4):1020–1023.

    CAS  PubMed  Google Scholar 

  21. Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol 1997; 15(2):84–88.

    Article  CAS  PubMed  Google Scholar 

  22. Lamm DL, Blumenstein BA, Crawford ED et al. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol Oncol 1995; 1:119–126.

    Google Scholar 

  23. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19(3):573–580.

    CAS  PubMed  Google Scholar 

  24. Lamm DL. Bladder cancer: twenty years of progress and the challenges that remain. CA Cancer J Clin 1998; 48(5):263–268.

    Article  CAS  PubMed  Google Scholar 

  25. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163(4):1124–1129.

    Article  CAS  PubMed  Google Scholar 

  26. Lamm DL. Management of bladder cancer. J Urol 2004; 171(6 Pt 1):2482–2483.

    Article  PubMed  Google Scholar 

  27. Messing E, Kim KM, Sharkey F et al. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006; 176(2):500–504.

    Article  CAS  PubMed  Google Scholar 

  28. See WA, Miller JS, Williams RD. Pathophysiology of transitional tumor cell adherence to sites of urothelial injury in rats: mechanisms mediating intravesical recurrence due to implantation. Cancer Res 1989; 49(19):5414–5418.

    CAS  PubMed  Google Scholar 

  29. See WA, Chapman PH, Williams RD. Kinetics of transitional tumor cell line 4909 adherence to injured urothelial surfaces in F-344 rats. Cancer Res 1990; 50(8):2499–2504.

    CAS  PubMed  Google Scholar 

  30. See WA, Crist SA, Williams RD. Single-dose cyclophosphamide for the prevention of bladder tumor implantation in F344 rats: site of drug activity. Cancer Res 1991; 51(5):1378–1383.

    CAS  PubMed  Google Scholar 

  31. See WA, Crist SA, Boileau MA, Williams RD. Single-dose preoperative systemic cyclophosphamide for the prevention of bladder tumor implantation in F344 rats. Cancer Res 1991; 51(5):1373–1377.

    CAS  PubMed  Google Scholar 

  32. See WA. Intravesical recombinant tissue plasminogen activator for the prevention of implantation-mediated bladder tumor recurrence. Clin Exp Metastasis 1992; 10(2):99–109.

    Article  CAS  PubMed  Google Scholar 

  33. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol 1985; 57(6):680–685.

    Google Scholar 

  34. The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. Br J Urol 1994; 73(6):632–638.

    Google Scholar 

  35. Ali-El-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 1997; 79(5):731–735.

    CAS  PubMed  Google Scholar 

  36. Rajala P, Liukkonen T, Raitanen M et al. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study–Finnbladder III. J Urol 1999; 161(4):1133–1135.

    Article  CAS  PubMed  Google Scholar 

  37. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171(6 Pt 1):2186–90, quiz.

    Article  PubMed  Google Scholar 

  38. Tolley DA, Parmar MK, Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996; 155(4):1233–1238.

    Article  CAS  PubMed  Google Scholar 

  39. Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 1983; 129(3):505–509.

    CAS  PubMed  Google Scholar 

  40. Zincke H, Benson RC, Jr., Hilton JF, Taylor WF. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. J Urol 1985; 134(6):1110–1114.

    CAS  PubMed  Google Scholar 

  41. Lamm DL. Intravesical therapy for superficial bladder cancer: slow but steady progress. J Clin Oncol 2003; 21(23):4259–4260.

    Article  PubMed  Google Scholar 

  42. Burnand KG, Boyd PJ, Mayo ME, Shuttleworth KE, Lloyd-Davies RW. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol 1976; 48(1):55–59.

    Article  Google Scholar 

  43. Herr HW, Donat SM, Dalbagni G. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J Urol 2002; 168(3):978–980.

    Article  PubMed  Google Scholar 

  44. Smith JA, Jr., Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162(5):1697–1701.

    Article  PubMed  Google Scholar 

  45. Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C. Guidelines on bladder cancer. Eur Urol 2002; 41(2):105–112.

    Article  PubMed  Google Scholar 

  46. Oosterlinck W, Lobel B, Jackse G, Malmstrom PU, Stockle M, Strenberg C. [EAU Recommendations 2001. “Guidelines on bladder cancer”]. Prog Urol 2002; 12(5):1161–1163.

    CAS  PubMed  Google Scholar 

  47. Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol Nefrol 2004; 56(1):65–72.

    CAS  PubMed  Google Scholar 

  48. Madeb R, Golijanin D, Noyes K, et al Utilization and cost-effectiveness of same day intravesical chemotherapeutic instillation following transurethral resection of newly diagnosed bladder cancer. J Urol 175[4], 13. 2006.

    Google Scholar 

  49. Briesacher B, Kamal-Bahl S, Hochberg M, Orwig D, Kahler KH. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. Arch Intern Med 2004; 164(15):1679–1684.

    Article  PubMed  Google Scholar 

  50. Chang S, Long SR, Kutikova L et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004; 22(17):3524–3530.

    Article  PubMed  Google Scholar 

  51. Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 2003; 26(6):1847–1851.

    Article  PubMed  Google Scholar 

  52. Hillman AL, Schwartz JS, Willian MK et al. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996; 47(2):169–178.

    Article  CAS  PubMed  Google Scholar 

  53. Lyman GH, Berndt ER, Kallich JD et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005; 8(2):149–156.

    Article  PubMed  Google Scholar 

  54. Ozminkowski RJ, Marder WD, Hawkins K et al. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. Clin Ther 2004; 26(8):1341–1354.

    Article  PubMed  Google Scholar 

  55. Lamm DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000; 31 Suppl 3:S86–S90.

    Article  PubMed  Google Scholar 

  56. Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology 2000; 55(2):161–168.

    Article  CAS  PubMed  Google Scholar 

  57. Young MJ, Soloway MS. Office evaluation and management of bladder neoplasms. Urol Clin North Am 1998; 25(4):603–611.

    Article  CAS  PubMed  Google Scholar 

  58. Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology 2000; 55(2):161–168.

    Article  CAS  PubMed  Google Scholar 

  59. Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168(5):1964–1970.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Rochester, Rochester, NY, USA

    Ralph Madeb & Edward Messing

Authors
  1. Ralph Madeb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward Messing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward Messing .

Editor information

Editors and Affiliations

  1. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    Cheryl T. Lee

  2. Dept. Urology, University of Michigan Health System, E. Medical Center Dr. 1500 , Ann Arbor, 48109-0252, U.S.A.

    David P. Wood

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Madeb, R., Messing, E. (2009). Perioperative Intravesical Therapy. In: Lee, C., Wood, D. (eds) Bladder Cancer. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-417-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-417-9_10

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-988-8

  • Online ISBN: 978-1-59745-417-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation